Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Docetaxel + Prednisone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03834506 | Phase III | Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | Completed | USA | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 7 |
| NCT04100018 | Phase III | Docetaxel + Nivolumab + Prednisone Docetaxel + Prednisone | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) | Completed | USA | TUR | ROU | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT06925737 | Phase III | Docetaxel + Prednisone Ifinatamab deruxtecan | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | ESP | DNK | DEU | CZE | CHE | BRA | AUT | AUS | ARG | 12 |
| NCT06520345 | Phase III | Abiraterone + Methylprednisolone Docetaxel + Prednisolone Abiraterone + Dexamethasone Docetaxel + Prednisone Abiraterone + Prednisone 177Lu-J591 + Docetaxel + Prednisone 177Lu-J591 + Enzalutamide + Prednisone 177Lu-J591 + Abiraterone + Methylprednisolone 177Lu-J591 + Abiraterone + Dexamethasone 177Lu-J591 + Docetaxel + Prednisolone Enzalutamide + Prednisolone Enzalutamide + Prednisone 177Lu-J591 + Enzalutamide + Prednisolone Abiraterone + Prednisolone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisolone | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL) | Recruiting | USA | NZL | AUS | 0 |
| NCT05848011 | Phase II | Docetaxel + MGD019 + Prednisone Docetaxel + Prednisone | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | POL | GBR | FRA | ESP | BGR | BEL | AUS | 2 |
| NCT01619813 | Phase II | Docetaxel + Prednisone Pelareorep | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Completed | CAN | 0 |
| NCT06764485 | Phase III | Docetaxel + Prednisone Enzalutamide + Prednisolone Enzalutamide + Prednisone Abiraterone + Prednisone Docetaxel + Prednisolone Abiraterone + Prednisolone CC-94676 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (rechARge) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG | 7 |
| NCT02685267 | Phase II | Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) | Terminated | USA | 0 |
| NCT03761225 | Phase III | Docetaxel + Prednisone Docetaxel + Masitinib + Prednisone | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | Completed | ITA | FRA | CAN | 3 |
| NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |